Know What's Happening in Pharma
Know What's Happening in Pharma
Pharma Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Shionogi completes $2.5B acquisition of ALS drug Radicava
Shionogi has finalized a $2.5 billion purchase of global rights to the ALS therapy Radicava from Tanabe Pharma, adding a rare‑disease asset and a U.S. commercial platform that is expected to generate roughly $700 million in revenue starting fiscal 2026.
Also developing:
By the numbers: Lupin Limited acquires VISUfarma in undisclosed deal
The University of Texas at San Antonio has opened a precision clinical trial to evaluate rapamycin in non‑smoking, independently living seniors. Researchers hope the study will provide hard data on dosing and safety, moving the longevity drug from hype to proven therapy.
A recent industry report warns that AI‑driven drug discovery platforms are vulnerable to cyber‑attacks and data‑privacy breaches, citing outdated hardware, fragmented compliance frameworks, and supply‑chain pressures. The findings could force pharma firms to overhaul security protocols and accelerate regulatory engagement.
GlucoTrack, Inc. saw its Nasdaq‑listed shares climb 34.09% to $1.46 after reporting key milestones that set the stage for an Investigational Device Exemption (IDE) filing with the FDA in the second quarter of 2026. The company completed a first‑in‑human trial...
Tanabe Pharma announced that its oral investigational drug achieved positive results in a pivotal Phase 3 trial for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), two ultra‑rare phototoxic disorders. The study met its primary endpoint of reducing light‑induced pain episodes and...
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too. GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest...
The current meds help people eat fewer calories. That’s how they work for weight loss (yes they have weight independent effects like CVD reduction). The next frontier is helping burn more calories.
Researchers at Leiden University introduced microrobots only a few tens of micrometres long that can swim, steer and change shape without any onboard sensors or code, moving at roughly 7 µm per second. The breakthrough relies on a nanostructured chain design...
Lantern Pharma and its subsidiary Starlight Therapeutics received FDA clearance for the Investigational New Drug application of STAR-001, paving the way for a Phase 1 pediatric trial in central nervous system cancers. The announcement sent Lantern's Nasdaq‑listed shares down 10.04%...
Adjuvant pembrolizumab (Keytruda) continued to show a strong recurrence‑free survival (RFS) advantage in resected stage IIB/IIC melanoma, with median RFS not reached versus 59.2 months for placebo (hazard ratio 0.65). The 48‑month RFS rates were 68.7% with pembrolizumab compared with...
Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...
Recent meta‑analyses of roughly 100,000‑plus adults confirm that statins and other cholesterol‑lowering drugs cut cardiovascular events by about 30 percent relative risk, delivering an absolute 2 percent mortality benefit over four years—equivalent to one life saved for every 50 treated. The safety...
The U.S. Food and Drug Administration approved Novo Nordisk’s 7.2 mg semaglutide injection, branded Wegovy HD, just 54 days after filing. The fast-track decision, the fourth under the National Priority Voucher program, expands dosing options for weight‑loss and metabolic biohackers.
Researchers from Northwestern, Rice and Carnegie Mellon unveiled HOBIT, a gum‑sized implant that keeps engineered cells alive and releases three biologics—an anti‑HIV antibody, a GLP‑1 peptide and leptin—for a month in animal trials. The device maintained 65% cell viability versus...
Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration granted accelerated approval for KRESLADI, its one‑time gene therapy for severe leukocyte adhesion deficiency‑I in children. The milestone triggered a swing in the company's stock, with a pre‑market surge followed...
β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights https://t.co/pPCdm2AcFo https://t.co/mPtz1Xqiep
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development Who is winning AI race again? https://t.co/ZW4S2zUGkS
China Shineway Pharmaceutical Group Limited announced a full‑year net profit of RMB949.95 million (about $133 million), up from RMB840.05 million a year earlier. The gain came even as revenue slipped 17% to RMB3.135 billion ($439 million), highlighting a mixed performance in China's generic drug market.
A meta‑analysis of 28 randomized trials involving 2,130 Asian patients shows that total glucosides of paeony (TGP) combined with conventional therapy significantly improves spinal function, reduces inflammatory markers such as ESR and CRP, and enhances quality‑of‑life scores in ankylosing spondylitis...
Cell and gene therapy (CGT) manufacturing is advancing quickly, yet many early‑stage firms postpone building an integrated digital backbone. The resulting manual handoffs create safety, compliance, and scalability risks. SAP’s Cell and Gene Therapy Orchestration platform introduces guided workflows, e‑signatures,...
Ocugen announced completion of patient enrollment for its Phase 3 liMeliGhT trial of OCU400, a modifier gene therapy for retinitis pigmentosa. The study enrolled 140 patients in a 2:1 treatment‑to‑control ratio and will assess visual function via the LDNA mobility test....
SELLAS Life Sciences announced it will present preclinical data on its CDK9 inhibitor SLS009 (tambiciclib) at the AACR 2026 meeting in San Diego. The poster highlights the drug’s ability to induce apoptosis and lower MCL‑1 levels in acute myeloid leukemia...
For years, we’ve talked about a trillion-dollar bioeconomy. The harder question has always been where to start. This new piece on the AB4S Molecule Manifesto from @LOrealGroupe, @Lallemande, @EITFood , @BASF, @Evonik, and @cradlebio offers one of the most compelling answers...
Rosen Law Firm has filed a securities‑fraud class action against Corcept Therapeutics and opened a class‑action investigation into Aldeyra Therapeutics following FDA setbacks. The actions give investors a chance to seek compensation and set a deadline of April 21, 2026...
Researchers at Ruhr University Bochum, Houston Methodist and the University of Johannesburg have unveiled three nanomedicine platforms—a light‑activated copper nanoparticle, a magnetically guided superparamagnetic carrier and a liposome‑encapsulated photodynamic therapy—that each claim to dramatically improve precision for cancer or spinal‑cord...
![[Comment] New Hope for Neurotrophin Targeting in Osteoarthritis Pain?](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/754aaf1faeb0d5f3b76618daddf79401.webp)
Osteoarthritis (OA) remains a massive global health challenge with no disease‑modifying drugs and only modestly effective analgesics. The anti‑NGF monoclonal antibody, introduced in 2010, delivered unprecedented pain relief but was halted in 2021 after the FDA and EMA flagged joint...
![[Editorial] Politicisation of the US FDA: Eroding Integrity and Trust](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/2cbcac9eecf69b15e3915028747699be.webp)
The editorial warns that increasing political interference is eroding the US Food and Drug Administration’s integrity and public trust. With a 2026 budget of $6.8 billion, the FDA remains the world’s most influential drug regulator, tasked with safeguarding safety while accelerating...
The Patented Medicine Prices Review Board (PMPRB) released seven proposed Practice Directions to modernize its hearing procedures. It proposes default paper hearings for evidentiary matters, electronic filing, standardized motions, AI disclosure, virtual oral arguments, and an expedited failure‑to‑file process with...
A recent study from Università Cattolica in Milan examined how open‑label placebos affect seniors aged 65 and older. Ninety participants were divided into deceptive placebo, open‑label placebo, and control groups for a three‑week trial. The open‑label group, informed they were...
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...
TrumpRx, launched early 2026, is a direct‑to‑patient portal offering more than 40 drugs with cash‑pay prices, coupons and discounts. The platform aligns with the administration’s most‑favored‑nation (MFN) pricing policy, but the listed prices do not always match the official MFN...
VIVAZEN® welcomed a House Energy and Commerce subcommittee hearing on H.R. 8000, the End Needless Distribution of 7‑OH Act, urging the DEA to promptly schedule the synthetic opioid 7‑hydroxymitragynine. The company highlighted public‑health risks such as toxicity, dependence and market confusion...
Korean biotech is gaining global visibility after the East‑West Biopharma Summit highlighted its first‑in‑class pipelines. The Korean Ministry of Health and Welfare announced that Eli Lilly will invest $500 million over the next five years to collaborate with domestic firms. The deal...
Rubedo Life Sciences reported positive preliminary Phase 1 data for RLS‑1496, the first human‑tested GPX4 modulator designed to clear senescent cells. The 4‑week, double‑blind study in the EU showed the drug was well‑tolerated, produced a clear dose‑response, and reduced epidermal thickness...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on five products: a subcutaneous formulation of Sanofi’s multiple‑myeloma therapy Sarclisa and four entirely new drugs pending approval. The subcutaneous version aims to simplify...
The White House has drafted a drug‑pricing bill and is privately meeting with more than a dozen major pharmaceutical companies to secure their backing. The proposed legislation mirrors voluntary pricing agreements the administration previously struck, and notably would allow cash‑paid...
At the 2026 American Academy of Dermatology meeting, phase 3 ADORING 1 and 2 trials demonstrated that once‑daily tapinarof cream significantly improves rash and itch in moderate to severe atopic dermatitis, with effects evident by week 1 and sustained through eight weeks. The studies...
In 1992, scientists discovered a chemical in Gila monster venom that mimicked GLP-1, the hormone your gut releases to signal fullness. By tinkering with its structure, pharma companies extended its duration from two hours (the Gila monster version) to one...
“Huntington’s Disease and The Triad of Therapeutic Conviction”. Debut blog from Eric Green, CEO of Trace Neuro, explaining why and how advances are happening in HD. Genetics, cellular understanding, and enabling modalities. https://t.co/pAr9EQs5gJ
In a recent FDA Q&A, Dr. Sarah Yim explained that the agency has now approved 50 biosimilars covering 15 reference biologics, spanning treatments from oncology to diabetes. She clarified the distinction between biosimilars and interchangeable biosimilars, noting that the latter...
This is so awesome. @JohnSchloendorn and Alice Gilman at R3 Bio talk through what they’re doing at R3 Bio: building something that's never existed before. They're designing genetically engineered whole organ systems. See them featured in WIRED. @WIRED full story here: https://t.co/8z5iGXR0uK
Early details of what's in the White House's drug pricing bill text — and who's getting a sneak peek of it https://t.co/Yt8usm4yOa
The FDA has approved an update to the neffy 1 mg epinephrine nasal spray label, eliminating the previous age minimum of four years. The only remaining eligibility criterion is a patient weight of at least 33 lb, covering children as young as...
Pharma firms are leveraging real‑world data (RWD) to map the patient journey of non‑small cell lung cancer (NSCLC) and uncover social determinants of health that hinder care. The new eBook highlights how gaps in biomarker testing, socioeconomic barriers, and incomplete...
Akeso Inc. announced a 51.5% year‑on‑year increase in 2025 commercial sales to RMB3.033 bn (about $425 m) and secured Chinese regulator clearance to launch Phase II trials of two first‑in‑class antibody‑drug conjugates. The results underscore the biotech’s rapid commercial expansion and its strategic...
AstraZeneca lung drug gets ‘surprise’ win in COPD trials https://t.co/QuRlOQtzdT @ByJonGardner $AZN $RGN $SNY $RHHBY
Agentic AI is emerging as a pivotal technology in healthcare, building on generative AI momentum. Xaira Therapeutics unveiled the largest virtual cell model to date, enhancing complex biology simulations. Researchers redesigned lipid nanoparticles to avoid the liver and concentrate in...
On March 27, 2026 BioWorld reported a flurry of regulatory actions affecting a broad swath of biopharma and med‑tech companies. The snapshot lists approvals, designations and submissions for firms such as 3D Systems, Agilent, Deciphera, Royal Philips and several others....
Johnson & Johnson’s Darzalex (daratumumab) received European Medicines Agency approval for self‑administration, becoming the first oncology injectable cleared for home use. The Type II label change allows patients or caregivers to give the subcutaneous injection after the fifth dose, covering all...
We can vibe-code cancer vaccines, and you think no one is going to be able to vibe-code a doomsday virus?
